Letrozole Actavis

Letrozole, the active ingredient in Letrozole Actavis, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, where it reduces estrogen production that can stimulate tumor growth. It is indicated for both metastatic and adjuvant treatment settings.

GNH USA supplies Letrozole Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, clinics and pharmacies worldwide, ensuring consistent quality, regulatory compliance and reliable logistics for global distribution.

Letrozole Actavis is an aromatase inhibitor used in the management of hormone‑dependent breast cancer.

Metastatic hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen levels to inhibit tumor progression. Adjuvant therapy for early‑stage hormone receptor‑positive breast cancer: decreases recurrence risk after surgery. Extended adjuvant therapy following 5 years of tamoxifen: provides continued estrogen suppression to lower late recurrence.

Letrozole Actavis may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: intermittent or persistent head pain. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe bone loss or osteoporosis: increased fracture risk. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Liver function abnormalities: elevated transaminases or hepatitis. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Myocardial infarction: rare heart attack occurrence.

When prescribing Letrozole Actavis, clinicians should observe several precautionary measures to ensure patient safety.

Assess bone health: monitor bone mineral density and consider calcium/vitamin D supplementation. Check liver function: perform baseline and periodic hepatic enzyme tests. Evaluate cardiovascular risk: review history of thromboembolic events or uncontrolled hypertension. Avoid use in pregnancy: contraindicated in pregnant women; ensure effective contraception. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Letrozole Actavis can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Estrogen replacement therapy: may counteract the estrogen‑lowering effect of letrozole. - Strong CYP2C19 inhibitors (e.g., fluconazole): can increase letrozole plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce letrozole exposure. - Anticoagulants (e.g., warfarin): monitor INR as letrozole may affect clotting parameters. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): observe for potential additive effects on bone health.